Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Eko Health has been advancing the use of artificial intelligence to help providers detect the early signs of disease, ...

Jered Threatin, who was behind a viral 2018 band hoax, has returned with new music while dealing with some very serious ...

In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) ...